The High-Resolution Electron Microscopy Facility (HREMF) was established in 1997 to provide a resource to investigators at the University of Texas M.D. Anderson Cancer Center for High-Resolution imaging of cells, tissues, and nanoscale particles that may be used as drug carriers or imaging agents. The goals of the facility are to provide a shared scanning electron microscopy and transmission electron microscopy resource for members of the M. D. Anderson Cancer Center. The facility occupies 388 sq ft in the R.E. """"""""Bob"""""""" Smith Research Building on the South Campus. A Director, a full-time Research Investigator, and a quarter-time Research Investigator staff the HREMF. The facility houses two electron microscopes: a Joel JEM1010 transmission electron microscope (TEM) and a Joel JEM5900 scanning electron microscope (SEM). Both of the microscopes are equipped with digital cameras that allow users to review their samples on computer monitors. The addition of digital imaging capability has significantly improved the efficiency of the facility and has rendered darkroom processing obsolete. Additional equipment needed to prepare samples for TEM and SEM, such as an ultramicrotome and ultrastainer, are also maintained within the facility. The facility's SEM is equipped with an electron backscatter detector and is the only microscope of its kind available on the M.D. Anderson campus. Similarly, the TEM is the only such microscope that is dedicated solely for research application. The institution acknowledges the value of the HREMF to the M.D. Anderson community by ensuring that the computers are equipped with the most current software and by contributing to the service contracts on the microscopes. The HREMF offers a number of services to our clients including: (a) consultation and assistance in constructing appropriate experimental designs for SEM and TEM, (b) processing of samples for SEM and TEM, (c) assistance with screening of samples, (d) assistance with data interpretation, (e) recommendations for future experiments, and (f) encouraging collaborations. During the previous funding period, HREMF services were used by 82 investigators from 11 of the CCSG programs, which represents a 55% increase over the previous 5-year period. The number of samples processed by the HREMF has increased three-fold since the facility was established in 1997. Peer-reviewed investigators are given priority for services and 74% had peer-reviewed funding and accounted for 52% of utilization. Future plans are focused on adapting new techniques to characterize bioengineered material and nanoparticles.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-36
Application #
8310872
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
36
Fiscal Year
2011
Total Cost
$138,463
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Qian, Xu; Li, Xinjian; Tan, Lin et al. (2018) Conversion of PRPS Hexamer to Monomer by AMPK-Mediated Phosphorylation Inhibits Nucleotide Synthesis in Response to Energy Stress. Cancer Discov 8:94-107
Dashti, S Ghazaleh; Win, Aung Ko; Hardikar, Sheetal S et al. (2018) Physical activity and the risk of colorectal cancer in Lynch syndrome. Int J Cancer 143:2250-2260
Livingston, J Andrew; Wang, Wei-Lien; Tsai, Jen-Wei et al. (2018) Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. Mol Cancer Ther 17:1315-1323
Childress, Merrida A; Himmelberg, Stephen M; Chen, Huiqin et al. (2018) ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. Mol Cancer Res 16:1724-1736
Zhang, Wei; Liu, Bo; Wu, Wenhui et al. (2018) Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res 24:696-707
Vijayaraghavan, Smruthi; Moulder, Stacy; Keyomarsi, Khandan et al. (2018) Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Target Oncol 13:21-38
Tsai, Edward; Robertson, Michael C; Lyons, Elizabeth J et al. (2018) Physical activity and exercise self-regulation in cancer survivors: A qualitative study. Psychooncology 27:563-568
Rosenstock, Aron S; Niu, Jiangong; Giordano, Sharon H et al. (2018) Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients. Cancer 124:899-906
Sanchez-Vega, Francisco; Mina, Marco; Armenia, Joshua et al. (2018) Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell 173:321-337.e10
Fleming, Nicole D; Nick, Alpa M; Coleman, Robert L et al. (2018) Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol 132:545-554

Showing the most recent 10 out of 12418 publications